General Archives - Page 50 of 2367

1 minute read

Enlivex Receives Regulatory Authorization For The Initiation Of A Placebo-Controlled Phase I/II Trial Evaluating Allocetra In Up To 46 Patients With Thumb Osteoarthritis

June 3, 8:43 AM

First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy Third study of AllocetraTM in osteoarthritis, following

ENLV

1 minute read

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential As A Precision Medicine For Cancer

By Benzinga Newsdesk

June 3, 8:38 AM

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE

CYCC

2 minute read

Why Is Boat Dealership Giant MarineMax’s Stock Soaring Today?

By Shivani Kumaresan

June 3, 8:29 AM

MarineMax shares surged as OneWater Marine reportedly in acquisition talks with a $40 per share all-cash offer. An official announcement is expected soon, although the deal is not yet finalized.

HZO

1 minute read

Scorpius And Beyond Imagination Announce Partnership To Utilize Autonomous AI-Powered Humanoid Robots For American Biomanufacturing

By Benzinga Newsdesk

June 3, 8:22 AM

Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor andenhance productivity through 24/7 operational capabilitiesBeyond's

SCPX

1 minute read

23andMe Therapeutics Present Preliminary Phase 2 Safety And Efficacy Results For 23ME-00610, Targeting CD200R1, At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

June 3, 8:21 AM

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and

1 minute read

Tonix Pharmaceuticals To Present New Data On Tonmya Suggesting Activity For Improvement In Fibromyalgia-Associated Depression Severity In An Oral Presentation At ASCP Annual Meeting

By Benzinga Newsdesk

June 3, 8:19 AM

Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addition, post-hoc analyses showed improvement in depression, anxiety, memory and energy

TNXP

1 minute read

Mainz Biomed Presents New Study Data For ColoFuture And eAArly DETECT Study Performance With Sensitivity For CRC Of 92% And 82% For Advanced Adenomas, Including 95.8% Detection Of High-Grade Dysplasia

By Benzinga Newsdesk

June 3, 8:16 AM

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled

MYNZ

2 minute read

EXCLUSIVE: Canadian Mineral Exploration Firm Pasofino Gold Completes Drilling At ‘Bukon Jedeh’ Gold Project In Liberia

By Vandana Singh

June 3, 7:40 AM

Pasofino Gold completes its diamond core drilling program at Bukon Jedeh gold camp in Liberia, a priority target within the Dugbe Gold Project. Eleven holes drilled, sampling ongoing with results expected in July 2024. Encouraging visual results observed.

EFRGF

1 minute read

Microsoft Plans $3.2B AI And Cloud Investment In Sweden: Report

By Shivani Kumaresan

June 3, 6:55 AM

Microsoft reportedly plans to invest 33.7 billion Swedish crowns ($3.21 billion) to upgrade its cloud and AI infrastructure in Sweden over the next two years. This marks Microsoft's largest investment in Sweden, focusing on technology enhancements and training 250,000 people in AI skills.

MSFT

2 minute read

Toyota Temporarily Halts Shipments And Sales Of Three Models In Japan After Government Finds Falsified Safety Data

By Benzinga Neuro

June 3, 6:28 AM

Despite confirming no performance issues that violate laws and regulations, Toyota has opted to halt shipments and sales of the three current models.